



Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA



Dipartimento di
Medicina Clinica e Sperimentale

CNR-IPCB
Istituto di Patologia Comparata e Biomedicina



UNA
UNIVERSITÀ
IN COLLABORAZIONE
CON
CARLO BO

The impact of N-Glycosylation in NeuroDevelopmental Disorders (NDDs): from diagnosis to target therapies

January 16-17, 2026

Catania - Italy

Rationale

Glycosylation is the most frequent post-translational modification of proteins and is essential for the development and function of the central nervous system (CNS). Congenital Disorders of Glycosylation (CDG) are a group of genetic CNS diseases caused by defects in the synthesis and attachment of glycans to proteins and lipids. CDG belong to the broader group of neurodevelopmental disorders (NDDs), whose genetic basis remains largely unknown.

The implementation of the NGLYNEU project will expand current knowledge on the functional impact of genetic variants involved in glycosylation in neurodevelopmental diseases. This will lead to the identification of new potential disease-causing genes and to the characterization of previously unrecognized neurodevelopmental disorders resulting from glycosylation defects.

The project's outcomes will contribute to broadening the boundaries of genetic CNS disorders and to identifying new molecular targets for their treatment.

PROGRAM

Opening Ceremony: Friday – 16th Jan 2026

Venue: Aula Magna – Monastero dei Benedettini - **Piazza Dante 32 - 95124 Catania**

15:30 Welcome and General information on the Scientific Program

Rita Barone (University of Catania, Italy)

15.40 Institutional Greetings

Chairs: *Domenico Garozzo (CNR Catania, Italy); Elena Barbieri (University of Urbino, Italy)*

16.00 Opening Keynote

Congenital Disorders of Glycosylation (CDG): Quo Vadis?

Eva Morava (Mount Sinai Hospital New York, USA)

Keynotes

16.30 Tourette Syndrome: a paradigm for NDD

Renata Rizzo (University of Catania, Italy)

17.00 IGF1 and IGF1 receptor glycosylation: emerging biomarkers of N-glycosylation defects

Giosuè Annibalini (University of Urbino, Italy)

Saturday – 17th Jan 2026

Venue: Aula Magna Torre Biologica – **Via Santa Sofia 98, Catania**

08.00 Participants' registration

Chairs: *Renata Rizzo (University of Catania, Italy); Corrado Romano (University of Catania, Italy)*

Session – Next-Generation Sequencing (NGS) AND Multi-OMIC ANALYSES IN UNDIAGNOSED PATIENTS WITH NDDs

9.00 Opening Keynote

Cracking the Code of CDG: Multi-Omic Models for Mechanism and Treatment

Tamas Kozicz (Mount Sinai Hospital New York, USA)

9.30 Targeted NGS analyses in the suspect of N-glycosylation disorders

Amelia Morrone (Meyer Children's Hospital Firenze, University of Florence Italy)

09:50 MAN2A2 mutation in cognitive disability

Simone Treccarichi (IRCCS Oasi Research Institute, Troina, Italy)

Keynotes

10:00 Bi-allelic versus mono-allelic mutation of glycogenes in patients with NDDs

Rita Barone (University of Catania, Italy)

10.30 Glycomic signature of N-glycosylation disorders

Luisella Sturiale (CNR Catania, Italy)

Q&A

11.10 Coffee-Break

Chairs: *R Barone (University of Catania, Italy); C. Spezia (CDG-Italia family association)*

Session – CDG: NOVEL PHENOTYPES, MODELS AND THERAPY DEVELOPMENT

11.45 Keynote

New treatment options in CDG, from bench to bedside

Eva Morava (Mount Sinai Hospital New York, USA)

12.15 NDDs phenotypes in N-glycosylation disorders

Lara Cirnigliaro (University of Catania, Italy)

12.35 Epileptic phenotypes in N-glycosylation disorders

Fabio Pettinato (University of Catania, Italy)

12.55 Peripheral Blood Mononuclear Cells (PBMC) analyses for metabolomic evaluation in PMM2-CDG

Angela Maria Amorini, Giuseppe Lazzarino (University of Catania, Italy)

13.15 CDG-Italia family Association

Caterina Spezia (Trapani, Italy)

Q&A

13.30 Light Lunch

Chairs Cettina Meli (*University of Catania, Italy*); Marco Fichera (*University of Catania, Italy*)

Session — EFFECTS OF GLYCO-GENES MUTATION AND INACTIVATION ON CELLULAR PROTEIN GLYCOSYLATION

15.00 Molecular characterization of VPS13B gene: assessing the impact of Cohen syndrome mutations on protein function

Fabiana Fanelli (University of Urbino, Italy)

15.20 Novel perspectives in the treatment of Cohen syndrome

Martina Randazzo (University of Catania, Italy)

15.40 Serum IgG glycosylation in patients with Cohen syndrome

Angelo Palmigiano (CNR Catania, Italy), Angela Messina (CNR Catania, Italy)

Q&A

16:15 Concluding Remarks

18:30 -19:00 Welcome Meeting with CDG-Italia family association

Novel clinical trials in CDG

Eva Morava and Tamas Kozicz (Mount Sinai Hospital New York)

19.45 Stay together and Dinner

Commentato [DG1]: taglierei qualche spazio per far stare tutto nella pagina



Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA



Dipartimento di
Medicina Clinica e Sperimentale

CNR-IPCB



UNIVERSITÀ
DEGLI STUDI
DI URBINO
CARLO BO

ORGANIZING AND SCIENTIFIC COMMITTEES

Amorini A M (Department of Biomedical and Biotechnological Sciences, Medical Biochemistry, University of Catania)

Annibalini G (Department of Biomolecular Sciences, University of Urbino Carlo Bo)

Barbieri E (Department of Biomolecular Sciences, University of Urbino Carlo Bo)

Barone R (Department of Clinical and Experimental Medicine, Child Neuropsychiatry, University of Catania)

Cirigliaro L (Department of Clinical and Experimental Medicine, Child Neuropsychiatry, University of Catania)

Fanelli F (Department of Biomolecular Sciences, University of Urbino Carlo Bo)

Fichera M (Department of Biomedical and Biotechnological Sciences, Medical Genetics, University of Catania)

Garozzo D (CNR Catania)

Kozicz T (Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York)

Lazzarino G (University of Catania)

Meli C (Inborn Metabolic Diseases - Newborn Screening Center - AOUP Catania)

Messina A (IPCB CNR Catania)

Morava E (Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York)

Morrone A (Laboratory of Molecular Genetics of Neurometabolic Diseases, Department of Neurosciences, Meyer Children's Hospital, Florence.)

Palmigiano A (IPCB CNR Catania)

Pettinato F (Department of Clinical and Experimental Medicine – Child Neuropsychiatry Section, University of Catania)

Randazzo M (Department of Clinical and Experimental Medicine – Child Neuropsychiatry Section, University of Catania)

Rizzo R (Department of Clinical and Experimental Medicine – Child Neuropsychiatry Section, University of Catania)



Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA



Dipartimento di
Medicina Clinica e Sperimentale



CNR **IPCB**
Istituto di Patologia Comparata e Biomedica

Romano C (Department of Biomedical and Biotechnological Sciences, Medical Genetics,
University of Catania University of Catania)

Saltarelli R (Department of Biomolecular Sciences, University of Urbino Carlo Bo)

Spezia C (CDG-Italia Family Association)

Sturiale L (IPCB CNR Catania)